These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36790480)

  • 41. Comparative genomic analysis of primary versus metastatic colorectal carcinomas.
    Vakiani E; Janakiraman M; Shen R; Sinha R; Zeng Z; Shia J; Cercek A; Kemeny N; D'Angelica M; Viale A; Heguy A; Paty P; Chan TA; Saltz LB; Weiser M; Solit DB
    J Clin Oncol; 2012 Aug; 30(24):2956-62. PubMed ID: 22665543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intestinal adenosquamous carcinoma with a synchronous skin metastasis: a immunohistochemical and molecular analysis.
    Parente P; Covelli C; Parrella P; Latiano TP; Fiordelisi F; Pellico MT; Maiello E; Graziano P
    Int J Colorectal Dis; 2020 Feb; 35(2):337-341. PubMed ID: 31823050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutational analysis of the BRAF gene in colorectal mucinous carcinoma in association with histological configuration.
    Yoshitake N; Fujii S; Mukawa K; Tominaga K; Fukui H; Ichikawa K; Tomita S; Ono Y; Imai Y; Terano A; Hiraishi H; Fujimori T
    Oncol Rep; 2007 Jan; 17(1):9-15. PubMed ID: 17143472
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
    Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
    PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E.
    Mesteri I; Bayer G; Meyer J; Capper D; Schoppmann SF; von Deimling A; Birner P
    Mod Pathol; 2014 Jan; 27(1):135-44. PubMed ID: 23887306
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.
    Rosty C; Young JP; Walsh MD; Clendenning M; Walters RJ; Pearson S; Pavluk E; Nagler B; Pakenas D; Jass JR; Jenkins MA; Win AK; Southey MC; Parry S; Hopper JL; Giles GG; Williamson E; English DR; Buchanan DD
    Mod Pathol; 2013 Jun; 26(6):825-34. PubMed ID: 23348904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Unique clinicopathologic and genetic alteration features in early onset colorectal carcinoma compared with age-related colorectal carcinoma: a large cohort next generation sequence analysis.
    Escobar D; Jones R; Gao J; Sun L; Liao J; Yang GY
    Hum Pathol; 2020 Nov; 105():37-46. PubMed ID: 32916163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
    Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
    Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC.
    Steinestel K; Lennerz JK; Eder S; Kraft K; Arndt A
    Virchows Arch; 2014 Aug; 465(2):155-63. PubMed ID: 24915895
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genomic alterations in signet ring and mucinous patterned colorectal carcinoma.
    Kim H; Kim BH; Lee D; Shin E
    Pathol Res Pract; 2019 Oct; 215(10):152566. PubMed ID: 31400926
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases.
    Karkouche R; Bachet JB; Sandrini J; Mitry E; Penna C; Côté JF; Blons H; Penault-Llorca F; Rougier P; Saint André JP; Emile JF
    Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1430-7. PubMed ID: 23114745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
    Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
    Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
    Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
    Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
    Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
    Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
    Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
    Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.
    Aparicio T; Svrcek M; Henriques J; Afchain P; Lièvre A; Tougeron D; Gagniere J; Terrebonne E; Piessen G; Legoux JL; Lecaille C; Pocard M; Gornet JM; Zaanan A; Lavau-Denes S; Lecomte T; Deutsch D; Vernerey D; Puig PL
    Int J Cancer; 2021 Apr; 148(7):1731-1742. PubMed ID: 33186471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
    Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
    APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.